Ziylo

Bristol, United Kingdom Founded: 2014 • Age: 12 yrs Acquired By Novo Nordisk
Biosensor platforms for carbohydrates are developed using photonics and optoelectronics.

About Ziylo

Ziylo is a Healthcare company based in Bristol (United Kingdom) founded in 2014, and was acquired by Novo Nordisk in August 2018. Biosensor platforms for carbohydrates are developed using photonics and optoelectronics. The company has 4 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Proteomics. Its legal entity is NOVO NORDISK RESEARCH CENTRE OXFORD LIMITED.

Company details

Ziylo was founded in 2014 and is located in Bristol, United Kingdom. Biosensor platforms for carbohydrates are created through integration of synthetic sugar-binding molecules, photonics, and optoelectronics. Fiber-optic chemical sensors are produced to support continuous sugar monitoring. Operations focus on sectors including point-of-care diagnostics, life science research, consumer products, and industrial biotechnology. The domain ziylo.com is maintained for company information.

  • Headquarters Bristol, United Kingdom
  • Employees 4
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website ziylo.com
  • Social LinkedIn X
  • Acquired by Novo Nordisk (Aug 2018)
  • Legal Name Novo Nordisk Research Centre Oxford Limited
  • Date of Incorporation 14 May, 2014
  • Jurisdiction OXFORD
Key Metrics

Funding Insights of Ziylo

  • Total Rounds 1
  • Last Round Grant β€” $718,835
  • First Round $718,835

    (Mar 2016)

  • Investors Count 1

All 1 funding rounds of Ziylo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2016$718,835Grant––
Valuation history

2 investors in total: 2 institutional.

Investors in Ziylo

Ziylo has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novo Nordisk and Innovate UK.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
innovateuk.gov.uk
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
1923novonordisk.comBagsvaerd, Denmark
Premium access

Investor details for Ziylo

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Ziylo

3 dated milestones of Ziylo across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ziylo is founded.
  2. Funding First funding round of $719K.
  3. Exit Acquired by Novo Nordisk.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Ziylo (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Nanopore-based electronic systems for single-molecule analysis are developed.
2005Oxford, Oxfordshire, United KingdomUSD 1.34 BUSD 301.49 M1,372
Genetically modified cell lines are developed using AAV gene-editing platform.
2007Cambridge, Cambridgeshire, United KingdomUSD 46.29 M
Biological reagents and antibodies are developed for life science research.
1998Cambridge, Cambridgeshire, United KingdomUSD 78.8 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ziylo

Premium access

Complete news archive for Ziylo

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ziylo

Ziylo was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Ziylo is headquartered in Bristol, United Kingdom. It is registered at Bristol, England, United Kingdom.

Ziylo has 4 employees.

Ziylo was founded in 2014 and is located in Bristol, United Kingdom. Biosensor platforms for carbohydrates are created through integration of synthetic sugar-binding molecules, photonics, and optoelectronics. Fiber-optic chemical sensors are produced to support continuous sugar monitoring. Operations focus on sectors including point-of-care diagnostics, life science research, consumer products, and industrial biotechnology. The domain ziylo.com is maintained for company information.

Ziylo has 2 investors. Key investors include Novo Nordisk, and Innovate UK.

Ziylo operates through Novo Nordisk Research Centre Oxford Limited.

Yes. Ziylo was acquired by Novo Nordisk in August 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available